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Topical application of imiquimod (IMQ) on the skin of mice induces inflammation with common features found
in psoriatic skin. Recently, it was postulated that IL-17 has an important role both in psoriasis and in the IMQ
model. To further investigate the impact of IL-17RA signaling in psoriasis, we generated IL-17 receptor A
(IL-17RA)–deficient mice (IL-17RAdel) and challenged these mice with IMQ. Interestingly, the disease was only
partially reduced and delayed but not abolished when compared with controls. In the absence of IL-17RA, we
found persisting signs of inflammation such as neutrophil and macrophage infiltration within the skin.
Surprisingly, already in the naive state, the skin of IL-17RAdel mice contained significantly elevated numbers of
Th17- and IL-17-producing gd T cells, assuming that IL-17RA signaling regulates the population size of Th17 and
gd T cells. Upon IMQ treatment of IL-17RAdel mice, these cells secreted elevated amounts of tumor necrosis
factor-a, IL-6, and IL-22, accompanied by increased levels of the chemokine CXCL2, suggesting an alternative
pathway of neutrophil and macrophage skin infiltration. Hence, our findings have major implications in the
potential long-term treatment of psoriasis by IL-17-targeting drugs.
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INTRODUCTION
Psoriasis is one of the most common chronic inflammatory
diseases of the skin, affecting 2–3% of the population
(Wagner et al., 2010). Up to now there is no cure known
for this disease, which is associated with extensive psycho-
logical and physical burden. This disease evolves over time in
a complex interplay of heterogeneous genetic and environ-
mental factors (Di Cesare et al., 2009). Psoriasis is not only a
skin disorder but may also include inflammation of the joints
in psoriasis arthritis (Winchester et al., 2008) and comorbid-
ities such as metabolic syndrome with increased insulin
resistance, increased cardiovascular risk (Vena et al., 2010;
Mehta et al., 2011), and an increased risk of mortality
(Gelfand et al., 2007).
Several risk factors and pathways are known to enable the
development of psoriasis. Genetic factors seem to have a role
when interacting with environmental factors such as drugs,
stress, or streptococcal infection (Griffiths and Barker, 2007).
Further, endogenous antimicrobial peptides (b-defensins and
cathelicidins) are overexpressed in psoriasis skin (Ong et al.,
2002; Griffiths and Barker, 2007). In complex with extra-
cellular self-DNA, these peptides seem to be able to evoke
autoimmunity by triggering plasmacytoid dendritic cells
(DCs) of the skin (Gilliet et al., 2008). In a mechanism not
yet fully understood, the IL-23/IL-17 axis is critically involved
in the development of human psoriasis (Blauvelt, 2008). Th17
cells are found in lesions from psoriatic patients (Harper
et al., 2009) and may be the key factors in psoriasis
(Di Cesare et al., 2009). In addition, clinical signs of psoriasis
can be induced in mouse skin by intradermal injection of the
IL-17-supporting cytokine IL-23 (Chan et al., 2006).
Apart from genetic approaches (Gudjonsson et al., 2007),
xenograft transplantation (Conrad and Nestle, 2006; Wagner
et al., 2010) or the IL-23-induced dermatitis model (Mabuchi
et al., 2011), imiquimod (IMQ)-induced psoriasis in mice,
represents a model that mimics the skin disease particularly
well (van der Fits et al., 2009; Cai et al., 2011). IMQ is a toll-
like receptor 7/8 ligand (Gilliet et al., 2004) and a potent
immune activator that is used for treatment of actinic
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keratosis and superficial basal cell carcinomas (Geisse et al.,
2002; Szeimies et al., 2004), but as a side effect it can
also provoke psoriasis-like skin flares in predisposed humans
(Wu et al., 2004). Daily topical application of IMQ on the
skin of mice leads to a psoriasis-like dermatitis with many
hallmarks of human psoriasis, such as the formation of
microabscesses, skin thickening, hyperkeratosis, acanthosis,
scaling, and erythema (Greaves and Weinstein, 1995;
Griffiths and Barker, 2007; van der Fits et al., 2009). This
model was shown to be critically dependent on the IL-23/
RORgt/IL-17 axis (van der Fits et al., 2009; Cai et al., 2011;
Pantelyushin et al., 2012) in mice of BALB/c or C57BL/6
background. IMQ application results in an increased
dermal proliferation and infiltration of neutrophils, mono-
nuclear cells, CD4þ T cells (especially Th17 cells), CD11cþ
DCs, plasmacytoid DCs, and modified differentiation of
keratinocytes. In addition to Th17 cells, gd T cells producing
IL-17A were recently shown to have a pivotal role in the
development of psoriasis (Mabuchi et al., 2011; Pantelyushin
et al., 2012). In the murine skin, gd T cells are present in
the epidermis (Hayday and Tigelaar, 2003), where they
have a dendritic morphology, and therefore have been
named dendritic epidermal T cells (Havran and Jameson,
2010). In addition, they exist in the dermis of mice as well—
that is the place where they are located in the human skin
(Ebert et al., 2006). Cai et al. (2011) recently showed that it is
mainly the innate dermal gd T cells that are the major
IL-17A–producing cells in the skin after IL-23 injection. The
frequency of IL-17A-producing dermal gd T cells in humans
suffering from psoriasis was increased in comparison with
healthy controls (Cai et al., 2011). In addition, it was shown
that dermal gd T cells were obligatory for the IL-23-initiated
disease, whereas both gd and ab T cells did have important
roles in the IMQ model (Cai et al., 2011; Mabuchi et al.,
2011).
It was previously shown (van der Fits et al., 2009) that IL-
17RA-deficient mice develop reduced erythema, scaling, and
skin thickening under IMQ treatment. Furthermore, the same
group also found that the number of infiltrating GR1þ
neutrophils in the dermis was reduced in comparison with
the control group. Here, we describe a mouse strain in which
the IL-17RA can be deleted in a Cre-dependent manner.
These mice were crossed so that the IL-17RA was inactivated
in the germ line, thus resulting effectively in IL-17RA
knockout mice, herein termed IL-17RAdel mice. Naive
IL-17RAdel mice contained massively elevated levels of
Th17- and IL-17A-producing dermal gd T cells in the skin.
Increased numbers of Th17 and gd T cells in lymph nodes and
spleen were present, indicating that signaling via IL-17RA
regulates the size of these populations in the skin and in other
organs. We found that in these mice the IMQ-induced
disease was clinically reduced, but signs of inflammation
such as infiltration of neutrophils and macrophages persisted
in the skin. Importantly, we found significantly elevated
levels of IL-6, IL-22, and CXCL2 in the skin of IMQ-treated
IL-17RAdel mice compared with controls, thereby revealing
an alternative pathway for psoriasis development in the
absence of IL-17RA signaling.
RESULTS
The IL-17RAdel mice
Th17 cells are key factors in psoriasis as demonstrated by
clinical and experimental data (Di Cesare et al., 2009;
Waisman, 2012). IL-17A is the hallmark cytokine of Th17
cells and is produced by gd T cells in addition (Jensen et al.,
2008). In addition to IL-17A, Th17 cells were shown to
express IL-17F, IL-21, IL-22, and IL-6 (Waisman, 2011).
IL-17A and IL-17F are structurally and genetically very
similar, and can both bind to the heterodimeric IL-17RA/IL-
17RC receptor (Iwakura et al., 2011; Zepp et al., 2011). To
delete IL-17RA, we flanked exons 4–7 with loxP sites (see
Figure 1a and Supplementary Fig S1 online). The neomycin
resistance cassette, necessary during the generation process
of the mouse strain, was removed by Flippase Recognition
Target (FRT) sites using Flippase recombinase. The resulting
mouse is thereafter named IL-17RAFl mouse. Crossing this
mouse strain to the deleter Cre mouse (Schwenk et al., 1995)
resulted in a germ line–transmitted complete deletion of the
IL-17RA gene, herein named as the IL-17RAdel strain (Figure
1a and Supplementary Fig S1 online). Reverse transcripta-
se–PCR was applied to RNA of spleens of wild-type (WT), IL-
17RAFl, and IL-17RAdel mice with primers that bind to exon 4
and 8. In IL-17RAdel mice, no PCR product could be detected,
whereas the IL-17RAFl mice expressed the IL-17RA receptor
in a manner similar to WT control mice (Figure 1b).
Psoriasis-like disease in the absence of IL-17RA signaling
Recently, it was reported by van der Fits et al. (van der Fits
et al., 2009) that application of IMQ-containing Aldara cream
results in a psoriasis-like disease that is dependent on the
IL-17/IL-23 cytokine axis. To test whether IL-17RAdel mice are
resistant to this skin inflammatory disease, we applied IMQ
containing cream once daily on the shaved back skin and on
the ears of the mice for 4–9 consecutive days, as described by
van der Fits et al., 2009. Mice were used at 7 and 8 weeks of
age at the start of treatment. IL-17RAdel mice showed a
significantly reduced erythema on day 4 (Figure 1c), but
surprisingly other scoring parameters such as skin thickness
or scaling were only mildly reduced in IL-17RAdel mice
compared with WT C57BL/6 control mice (Figure 1d). These
findings are summed as the cumulative psoriasis area and
severity index (PASI) score (combining the three parameters),
which was significantly reduced only up to day 4 of disease
(Figure 1d) in IL-17RAdel mice compared with controls.
Application of sham cream (containing all ingredients as the
IMQ cream except for the active component) did not lead to
any sign of skin inflammation in both WT and IL-17RAdel
mice.
To further quantify the epidermal hyperplasia, we per-
formed blinded measurements of the epidermal thickness on
the basis of hematoxylin and eosin–stained slices from mice
treated with IMQ for five consecutive days. In both IMQ-
treated groups, WT and IL-17RAdel mice, the epidermal
thickness was significantly higher than in sham-treated WT
mice (Figure 1e). In line with the skin thickness measure-
ments shown in Figure 1d, the difference between WT and
IL-17RAdel mice after treatment was minor (WT mice had
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2.9 times and IL-17RAdel mice 2.6 times thicker epidermis
than sham-treated WT mice). The hematoxylin and eosin
staining show the appearance of hyperkeratosis, acanthosis,
and microabscesses in IMQ-treated WT and IL-17RAdel mice
(Supplementary Figure S2 online).
To validate the results of our IMQ-induced model and to
test whether a more defined model of disease pathogenesis
would be similarly independent of IL-17RA signaling, we
used the IL-23 injection model as described before (Chan
et al., 2006). After intradermal IL-23 injection for seven
consecutive days in the ears of WT and IL-17RAdel mice, we
detected a significant increase in the ear thickness in mice of
both groups compared with the phosphate-buffered saline-
treated mice (Figure 1f). In line with the IMQ model,
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Figure 1. IL-17RAdel mice show a milder form of imiquimod (IMQ)-induced psoriasis in comparison with control mice. (a) Construction of the IL-17RAdel
mouse strain: exons 4–7 of the mouse IL-17RA gene are flanked by LoxP sites, indicated by blue triangles (IL-17RAFl). After crossing this mouse strain with
a Deleter Cre mouse, exons 4–7 (red boxes) are deleted. Exons are indicated as boxes. The small oval indicates the Flippase Recognition Target site,
which flanked the neomycin resistance cassette during the generation process of this mouse line and is removed in the IL-17RAFl and the IL-17RAdel mice.
(b) IL-17RAdel mice express no wild-type (WT) IL-17RA messenger RNA (mRNA) in reverse transcriptase (RT)–PCR: IL-17RAFl mice show normal levels of
IL-17RA mRNA (lanes 1 and 2) compared with WT (lane 4). In contrast, IL-17RAdel mice (lane 3) do not express IL-17RA mRNA. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as internal control. (c) Phenotypical presentation of mouse back skin of 8-week-old WT and IL-17RAdel mice that were
treated with IMQ on the shaved and depilated back skin and on the right ear over 7 days. The photo was taken on day 4. Mouse one was the internal sham-
treated control in each group, which shows no disease development. (d) Daily scoring of scaling, skin thickness, and erythema of IL-17RAdel and control mice
under IMQ treatment over 8 days. The cumulative psoriasis area and severity index (PASI) includes scaling, skin thickness, and erythema of IMQ-treated animals.
Scale from 0 to 4. Shown is the mean±standard deviation (SD; n¼4 per experiment, representing three independent experiments with comparable results; the
statistical analysis of significance is described in the methods section). (e) Microscopical quantification of epidermal hyperplasia after 5 days of treatment (n¼ 3,
blinded measurements were performed at three different regions and do not include the stratum corneum to avoid measurement falsification due to fixation
artifacts). (f) Ears of WT and IL-17RAdel mice were injected intradermally for 8 days with 20 ml phosphate-buffered saline (PBS), alone or containing 500 ng IL-23.
Ear thickness was measured daily and shows percentagewise increase of the starting values (n¼3, significance is shown in comparison with the PBS-treated WT
control).
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inflammation in the IL-23 injection model was delayed by
1 day only in IL-17RA-deficient mice compared with control
mice without showing a significant difference in ear thickness
on the individual days.
Cellular infiltrates in the IMQ model
Next, we analyzed cellular infiltrates in the skin of IMQ-
treated ears after 8 days of treatment. When analyzed on day
9 of IMQ treatment, we detected an increased frequency of
CD11bþ cells in both mouse groups in comparison with the
sham-treated mice (Figure 2a–c). Interestingly, we found
significantly more CD11bþ cells in the ears of the IL-17RAdel
mice in comparison with IMQ-treated WT animals (Figure
2a–c). These infiltrates were composed mainly of macro-
phages but also of inflammatory monocytes and GR1hi
neutrophils (Figure 2a, right). Despite the higher number of
CD11bþ cells in IMQ-treated IL-17RAdel mice compared
with controls, the composition of myeloid cellular infiltrates
was not significantly altered (Figure 2a, right) compared with
IMQ-treated WT mice (Figure 2b and c). As plasmacytoid
DCs are implicated in disease development following IMQ
treatment, we stained and quantified plasmacytoid DCs of
these animals on day 5 of treatment and found similar
numbers of plasmacytoid DCs in WT and IL-17RAdel mice
(Supplementary Figure S3 online). We further histologically
analyzed the skin for the infiltration of neutrophils (Figure 2d)
and macrophages (Figure 2e). As seen in these figures, the
skin of WT and IL-17RAdel mice treated with the sham cream
contained considerable numbers of these innate cell popula-
tions, reflecting the effect of the nonspecific irritation of the
sham treatment. Once treated with IMQ-containing cream,
the levels of both neutrophils and macrophages were
drastically increased in both mouse groups. These data
clearly show that at this time point of disease the lack of
IL-17RA signaling does not mitigate infiltration of innate
myeloid cells, which points to alternative mechanisms of
disease in these mice.
Deletion of IL-17RA results in increased number of
IL-17A-producing cells in the skin of IMQ-treated mice
Our findings demonstrate that mice lacking signaling via the
IL-17RA are susceptible to IMQ-induced psoriasis-like
disease, which is further manifested by accumulation of
innate immune cells in the skin. Although IL-17 signaling
is impeded in these mice, IL-17-producing cells may be
involved in this inflammatory process by the secretion of
other inflammatory cytokines. Indeed, we found that the skin
of sham-treated IL-17RAdel mice contained high numbers of
CD4þ T cells (Figure 3b), of which about 50% also expressed
IL-17A as seen by intracellular staining (Figure 3a). In
contrast, sham-treated WT mice were, as expected, devoid
of Th17 cells in the skin, and only after treatment with IMQ
showed a small but significant infiltration of these cells. Upon
treatment with IMQ, the skin of IL-17RAdel mice retained a
level of about 40% Th17 cells of the total CD4 T cells, but it is
noteworthy that the total number of CD4 cells was highly
increased compared with WT mice (Figure 3b and c). We
also analyzed these mice for systemic effects of the IMQ
treatment on cytokine-producing CD4 and gd-T cells. In
agreement with previous reports describing a higher level of
IL-17A in the serum and the lung and higher differentiation of
Th17 cells in vitro in IL-17RA KO animals (Ye et al., 2001;
Nagata et al., 2008; Smith et al., 2008), we found highly
increased levels of IL-17A-expressing Th17 and gd T cells also
in our sham-treated IL-17RAdel animals. Upon IMQ treat-
ment, only Th17 cells in the lymph nodes further increased in
these animals (Supplementary Figure S4 online) as compared
with control mice.
gd T cells have been described in the skin of untreated
mice (Hayday and Tigelaar, 2003) and were recently
implicated in IMQ-induced psoriasis-like disease in mice
and in human psoriasis patients (Cai et al., 2011; Pantelyush-
in et al., 2012). We were therefore interested to analyze
whether these cells can also be found in the skin of the IL-
17RAdel mice. In mice, dermal gd T cells can be easily
distinguished from the dendritic epidermal T cells by the
expression level of the gd T-cell receptor, with low expression
marking the dermal gd T cells. As can be seen in Figure 3a,
we found by intracellular staining a clear population of IL-
17A-producing gd T cells in WT mice (Figure 3a, right). In
contrast to the Th17 cells, the proportion of IL-17Aþ gd T
cells increased much more in WT mice after IMQ treatment,
as reported previously (Cai et al., 2011). Similar to the Th17
cells, we also found a high proportion of dermal gd T cells in
the skin of the sham-treated IL-17RAdel mice, which only
slightly changed after treatment (Figure 3a). The total number
of the IL-17Aþ gd T cells were similar after IMQ treatment in
WT and IL-17RAdel mice (Figure 3c). We further analyzed
IL-17A expression on day 9 of IMQ treatment by immuno-
histochemistry. As expected by the flow cytometry data,
sham-treated IL-17RAdel mice showed high levels of IL-17A
production (Figure 3d), partially coassociated with increased
numbers of CD4 T cells. Upon IMQ treatment, IL-17A levels
in the skin further increased in IL-17RAdel mice, similar to
CD4 levels (Figure 3d), but at this late time point barely no
IL-17A staining was detectable by immunofluorescence in
IMQ-treated WT mice. As IL-17A-positive cells only partially
overlapped with CD4þ T cells, gd T cells were probably
responsible for the residual increase in IL-17A in the skin
under IMQ treatment.
IMQ-treated IL-17RAdel mice exhibit high levels of IL-6
and IL-22 in the skin
As signaling of both IL-17A and IL-17F via IL-17RA is
interrupted in IL-17RAdel mice, we wondered whether other
cytokine-mediated signaling pathways might account for the
disease seen in these animals after IMQ application. We
therefore analyzed the messenger RNA expression of several
proinflammatory cytokines and chemokines in the skin of
IMQ-treated mice by reverse transcriptase–PCR. As expected
by the flow cytometry data, IL-17A messenger RNA expres-
sion was greatly enhanced in the skin of IL-17RAdel mice
compared with control animals (Figure 4). Further, the
expression of the proinflammatory cytokines IL-22 and IL-6,
as well as the chemokine CXCL-2, was strongly upregulated
in IMQ-treated IL-17RAdel mice compared with IMQ-treated
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Figure 2. Invasion of neutrophilic granulocytes and macrophages to the skin of imiquimod (IMQ)-treated mice. IL-17RAdel and control mice in comparison
with sham-treated controls after 8 days of treatment. (a) Flow cytometric analysis of the ear skin using the indicated antibodies. Right: CD11bþ gated cells
showing GR1þ granulocytes and F4/80þ monocytes/macrophages. Panels are representative for three independent experiments including 3–4 mice each with
comparable results. (b) CD11bþ cells invading the ears of IMQ- and sham-treated wild-type (WT) and IL-17RAdel mice shown as percentage of acquired cells of
the live gate (analyzed with one-way analysis of variance (ANOVA)). (c) Total number of CD11bþ cells and GR1þ granulocytes in the ears of IMQ- and sham-
treated WT and IL-17RAdel mice (analyzed with one-way ANOVA). (d, e) Immunofluorescence of back skin crysosections of IL-17RAdel and control mice after 9
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magnifications are presented. Bar¼ 100 mm; in highest original magnification bar¼ 50mm.
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WT mice. IL-6, IL-22, and CXCL-2 were shown to be
associated with skin inflammation and neutrophil recruitment
to sites of inflammation (Luttikhuizen et al., 2007; Di Cesare
et al., 2009). In addition, also tumor necrosis factor-a was
similarly high in IL-17RAdel mice as in WT IMQ-treated
animals. In contrast, we found a significantly lower expres-
sion of IL-23p19, CCR6, and GM-CSF in the skins of IMQ-
treated IL-17RAdel mice compared with IMQ-treated WT
mice (Figure 4). The lower GM-CSF is in line with the lack of
a functional receptor for IL-17A in these mice, as
this cytokine is secreted in response to IL-17 signaling
(McGeachy, 2011).
Sources of IL-6 and IL-22 in skin of IMQ-treated animals
We aimed to determine the cellular source of IL-6 in the skin
of these mice. By intracellular staining, we found significantly
more skin-infiltrating dermal (gd-TCRlo) and epidermal
(gd-TCRhigh) gd T cells (Figure 5a and b). We also found
an increase in IL-6-producing CD4 T cells in IMQ-treated
IL-17RAdel mice when compared with WT mice (Figure 5b) or
with sham-treated IL-17RAdel mice. We further stained skin-
infiltrating cells for IL-22 in conjunction with IL-17A and
found that IL-22 was expressed by dermal gd T cells (Figure
6a and b) and by CD4þ T cells (Figure 6c). Notably, the
proportion of dermal gd T cells and CD4 T cells that produce
IL-22 in IMQ-treated IL-17RAdel mice is significantly higher
compared with IMQ-treated control animals (Figure 6d).
These findings suggest that, although IL-17 cytokines
produced by ab and gd T cells are unable to signal via IL-
17RA, the expanded cells in IL-17RAdel that express these
cytokines may contribute to the pathogenic process in the
skin by producing other proinflammatory cytokines, such as
IL-6 and IL-22.
DISCUSSION
Our results demonstrate that a complete deletion of the IL-17
receptor A chain (IL-17RAdel mice) results in delayed and
milder IMQ-induced psoriasis—but nevertheless the disease
develops also without IL-17 signaling via IL-17RA. Most
likely, the disease develops via elevated amounts of cytokines
such as IL-6, IL-22, and the chemokine CXCL2, secreted by
IL-17-producing ab and gd T cells.
The IMQ-induced psoriasis-like mouse model recapitu-
lates many hallmark features of human psoriasis, including
clinically hyperkeratosis, erythema, and scaling, and immu-
nologically neutrophil microabscesses and infiltration of gd
T cells and Th17 cells to the skin (van der Fits et al., 2009).
This model is used to induce a fast, reproducible, and efficient
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psoriasis-like pathology, which is based on the IL-23/IL-17
axis (Shear et al., 2008). van der Fits et al. (2009) showed that
the IMQ-induced skin inflammation in mice with a complete
deletion of the IL-17RA receptor is profoundly suppressed
compared with WT control mice. Here we show that the
PASI score of IL-17RAdel mice is significantly reduced in
comparison with the control group when treated with IMQ,
but that there is no reduction of the IMQ-induced skin
thickening and from day 4 onward there is no difference in
scaling between the two groups.
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Figure 4. Expression of cytokines in the back skin of imiquimod (IMQ)-treated IL-17RAdel control mice after 7 days of treatment. Quantitative real-time
reverse transcriptase (RT)–PCR analysis of the indicated genes in the skin of IMQ-treated IL-17RAdel mice in comparison with IMQ-treated control mice.
Expression level shown relative to the housekeeping gene HPRT (n¼ 4 from two independent experiments with comparable results).
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It was shown that in IL-17RA KO mice both mobilization of
peripheral neutrophils and their influx to infected organs is
significantly impaired and delayed (Huang et al., 2004). How-
ever, this does not mean that the neutrophil invasion or activation
is completely abolished in fungal or bacterial infection—only that
it is weakened and milder. In addition, the level of macrophage
inflammatory protein in the serum of Toxoplasma gondii–infected
IL-17RA KOmice was lower compared with controls but was not
abolished (Kelly et al., 2005). The latter is in agreement with our
findings showing a mild development of IMQ-induced psoriasis
in the IL-17RAdel mice. Nevertheless, also under conditions of
IL-17RA deletion, activated neutrophils and macrophages are
attracted to the site of inflammation.
Although IL-17C can also attract neutrophils when
injected into the skin (Ramirez-Carrozzi et al., 2011), this
cytokine cannot be attributed to neutrophil attraction in
IL-17RAdel mice, as IL-17C signaling, similar to that of IL-17A,
F, and E, depends on IL-17RA (Chang et al., 2011; Iwakura
et al., 2011; Song et al., 2011). In the absence of IL-17A/F/E/C
signaling, other cytokines secreted or induced by the elevated
levels of IL-17A-producing gd T cells and Th17 cells may take
over. IL-6 is known to promote neutrophil induction and
activation both in vivo and in vitro (Romani et al., 1996). This
proinflammatory cytokine was detected more than 20 years
ago in human psoriatic lesions, and it was suggested that IL-6
enhances keratinocyte proliferation (Grossman et al., 1989;
Kishimoto et al., 1992). Moreover, IL-6 is an important factor
to switch differentiation of monocytes from DCs to macro-
phages (Chomarat et al., 2000) and contributes to neutrophil
recruitment (Hurst et al., 2001). The increased level of IL-6 in
the skin of IMQ-treated IL-17RAdel mice compared with
treated WT skin supports a possible role of IL-6 in disease
development in the absence of IL-17RA signaling.
The pivotal role of gd T cells in human psoriasis has
been stressed recently (Cai et al., 2011). Cai et al. showed
that, upon IL-23 stimulation, dermal gd T cells produce
IL-17A, which leads to disease progression in mice. In
psoriasis patients, the numbers of gd T cells are also elevated
in the affected skin and produce large amounts of IL-17A. gd
T cells not only promote inflammation via IL-17 but are
also known to produce IL-22 (Mabuchi et al., 2011;
Ness-Schwickerath and Morita, 2011). IL-22 signals to
keratinocytes causing their activation and hyperproliferation.
Activated keratinocytes produce downstream proinflamma-
tory cytokines, chemokines, and also antimicrobial peptides,
which are able to recruit immune cells to the inflammed skin,
where they are in turn activated (Zheng et al., 2007; Nograles
et al., 2008).
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Figure 6. IL-22 production of T cells in the ear skin of imiquimod (IMQ)-treated IL-17RAdel and wild-type (WT) mice. (a) CD3þ T cells in the skin: cells
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It was previously shown that IL-17F binding to IL-17RA
regulates the production of IL-17A in vivo and that CD4 T
cells from IL-17RA KO mice produce higher amounts of
IL-17A in vivo (Nagata et al., 2008). It was also shown that
IL-17A or F treatment inhibits the expression of IL-17A (Smith
et al., 2008). In line with this, we not only found increased
systemic levels of IL-17A in the IL-17RA-deficient mice but
also increased numbers of IL-17A-producing CD4þ and gd
T cells in the skin, LN, and spleen of these mice, even when
naive. The reason for this increase of IL-17A-producing
T cells is not yet clarified and is a subject of further
investigation in our laboratory. Despite the initially elevated
numbers of IL-17-competent cells, there is no skin inflamma-
tion in untreated IL-17RAdel mice, and only when we apply
IMQ psoriasis develops in these animals. This suggests that
IMQ indirectly activates the preexisting Th17 and gd T cells,
which secrete, in addition to IL-17, other cytokines such as
IL-6 and IL-22 that initiate psoriasis independent of IL-17.
In conditions of IL-17RA deficiency, the effect of the Th2-
associated IL-17E (IL-25) is also weakened: IL-17E is usually
known as ‘‘protective’’ cytokine ameliorating diabetes
(Emamaullee et al., 2009) and suppressing experimental
autoimmune encephalomyelitis (Kleinschek et al., 2007).
Weakening the IL-17E effect may result in the activation
of a proinflammatory response, which could also add to
inflammation induced by IL-6 and IL-22 produced by the
elevated levels of IL-17-producing cells in the skin of
IL-17RAdel mice.
In addition to the classical therapeutic options that are
already in use for psoriasis, more selective anti-inflammatory
treatments such as anti-tumor necrosis factor-a (Gudjonsson
and Elder, 2008), anti-IL-6R (Tocilizumab), and anti-IL-12/IL-
23 (Ustekinumab) are already licensed. In addition, a
monoclonal antibody neutralizing IL-17A (Secukinumab) is
currently tested in clinical trials (Kurzeja et al., 2011). In light
of our findings, one might consider to monitor long-term anti-
IL-17A-treated patients for the development of increased
numbers of IL-17-producing gd T cells and Th17 cells.
In conclusion, we here demonstrate that IMQ-induced skin
inflammation appears in the absence of IL-17RA signaling.
Hence, besides the classical IL-23/IL-17 axis of neutrophil
recruitment to the skin, other efficient pathways of neutrophil
attraction and inflammation do exist, which are activated in
the absence of IL-17RA signaling. This compensatory process
should be taken into consideration when developing anti-
psoriatic drugs targeting the IL-17 signaling pathway.
MATERIALS AND METHODS
Mice
All animal experiments were conducted in accordance with the
guidelines of the central animal facility institution of the University
of Mainz.
Detection of IL-17RA
Total RNA from spleens of WT, IL-17RAFl, and IL17RAdel mice was
extracted using the RNeasy Mini Kit (Qiagen, Hilden, Germany).
One microgram of total RNA was reverse transcribed using the
SuperScript II reverse transcriptase (Invitrogen Life Technologies,
Paisley, UK) according to the manufacturer’s protocol using oligo
(DT) 12–18 primer. Complementary DNA was amplified with
the following primers specific for IL-17A receptor A (IL-17RA):
50-GCAGCTGAACACCAATGAGC-30 and 50-GCAGCACCAGTGAA
ACTTGC-30. Glyceraldehyde-3-phosphate dehydrogenase was used
as a reference gene (50-ACCACAGTCCATGCCATCAC-30 and 50-TAC
AGCAACAGGGTGGTGGA-30).
IMQ-induced psoriasis
Eight-week-old female mice (IL-17RAdel and controls) were shaved
and depilated on their back. One group was treated with Aldara
cream (Meda AB, Solna, Sweden) containing 5% IMQ and the other
with sham cream (Heib et al., 2007) on one ear (5mg) and on their
back (55mg) over 4–9 days once daily.
Intradermal IL-23 injections
We administered intradermal injection of 20ml of phosphate-
buffered saline containing 500 ng of recombinant mouse
IL-23 (eBioscience, San Diego, CA) into the ears of anesthetized
mice using a 30-gauge needle every day for eight consecutive days.
Before and after injection, ear thickness was measured daily. Values
of day 0 were taken as the starting value. Ear measurements were
taken at the center of the ears using a dial thickness gage (Mitutoyo,
Kawasaki, Japan). After 8 days, the mice were killed and tissue was
collected.
PASI score for mice
The human PASI score describes the degree of erythema, scaling of
skin, skin thickness, and affected area to characterize the severity of
psoriasis in patients. We used a modified PASI score for the IMQ-
induced psoriasis in mice consisting of the parameters skin thickness,
scaling, and erythema. The thickness of back skin was measured in
duplicates to triplicates using a thickness gage. A cumulative PASI
score or the individual score concerning one parameter (skin
thickness, scaling, erythema) is shown.
Flow cytometry
Skin was cleaned of fat tissue and incubated in a Liberase (Roche,
Basel, Switzerland) and DNAse solution (Sigma-Aldrich, St Louis,
MO) for 1.5 hours (back skin) or 1 hour (ears) before finally shredding
with gentleMacs Dissociator (Miltenyi Biotec, Bergisch Gladbach,
Germany). Lymph nodes and spleen were mechanically dissociated
to yield a single-cell solution and were treated with ammonium
chloride–potassium buffer for red blood cell lysis. Cells were treated
with Fc-block (eBioscience). Surface staining was performed with
CD11b ef450 (eBioscience), CD11b PE-Cy7 (eBioscience), CD11c
allophycocyanin (APC) (BD, San Diego, CA), PDCA-1 Bio (Miltenyi
Biotec), Streptavidin V500 (BD), Ly6c (BD), GR-1 APC
(eBioscience), F4/80 PE (eBioscience), B220 ef780 (eBioscience),
B220 PerCp (BD), CD3 PerCP (BD), CD4 V500 (BD), and gd T-cell
receptor FITC (BD). For intracellular cytokine staining, the cells were
activated for 4 hours in phorbol 12-myristate 13-acetate (50 ngml1)
and Ionomycin (750 ngml1) in the presence of Brefeldin A
(1mgml1). Thereafter, cells were surface-stained, washed, and
fixed in 2% paraformaldehyde in phosphate-buffered saline for
10minutes on ice. Cells were then permeabilized with saponine
buffer (0.1% saponine, 1% BSA, and 0.02% NaN3). Intracellular
staining was performed with IL-17A PE (eBioscience), IFN-g
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APC (BD), IL-22 PE (BioLegend, San Diego, CA), and IL-6 PE
(eBioscience) in saponine buffer. As intracellular isotype control,
IgG1,k PE (eBioscience) and IgG2a,k (eBioscience) were used.
Samples were acquired using a FACSCanto II flow cytometer (BD)
and analyzed with FlowJo (TreeStar, San Carlos, CA).
Real-time reverse transcriptase–PCR
Total RNA was isolated from the skin using the RNeasy Mini Kit
(Qiagen) after controlled crushing with Tissue Lyzer (Qiagen) and
Proteinase K (Qiagen) incubation. Complementary DNA was
prepared using the first-strand synthesis kit from Invitrogen Life
Technologies. One microgram of complementary DNA was used for
a quantitative real-time reaction using the QuantiTect SYBR Green
reaction mixture (Qiagen) on white 96-well plates (Roche) with
primer mixes from Qiagen as described on their homepage (https://
www1.qiagen.com/GeneGlobe/Default.aspx). Real-time PCR was
performed on a Roche Lightcycler 480II. The relative expression
levels of the respective samples to HPRT are calculated with the
delta-delta Ct method (Roche software) (Livak and Schmittgen,
2001).
Histology
Immunofluorescence of 10-mm cryosections was performed using the
fluorescence microscope Olympus IX81 (Olympus, Tokyo, Japan) and
the TSA Cy3 and TSA Fluorescein system (PerkinElmer, Waltham, MA)
as recommended by the company. The following primary antibodies
were used: F4/80 (BD), myeloperoxidase (Abcam, Cambridge, MA),
CD4 (BD), and IL-17A (Santa Cruz Biotechnology, Santa Cruz, CA).
The slides were incubated for 30minutes at room temperature with
the biotinylated secondary antibody (Dianova, Hamburg, Germany).
Nuclei were counterstained with Hoechst 33342 (Invitrogen).
Statistical analysis
Data were analyzed for statistical significance using either the two-
tailed unpaired Student’s t-test or where indicated using the one-way
analysis of variance test. Values of Po0.001, Po0.01, and Po0.05
were marked by three, two, and one asterisks (or rhomb), respectively.
Columns in figures represent means±standard deviation.
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